Literature Reviews
doi: 10.25005/2074-0581-2019-21-4-661-674
DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 2)

M.U. Sharofova1,2, Sh.S. Sagdieva1,2, S.D. Yusufi3

1Center for Research on Innovative Technologies under the Academy of Sciences of the Republic of Tajikistan, Dushanbe, Republic of Tajikistan
2Institute of Avicenna’s Medicine and Pharmacology, Dushanbe, Republic of Tajikistan
3Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The authors analyzed numerous scientific studies on the problem of type 2 diabetes mellitus (T2DM), the extent of the spread is causing concern among experts around the world. The review examines and analyses the causes of the unrelated increase in the incidence of this pathology, the high risk of severe complications, comorbidities and deaths, reasons for the increase in the prevalence of the disease among children. Taking into account insufficient effectiveness of medical treatment of T2DM using synthetic drugs, the authors cites information on herbal medicine diabetes. The second part of this review provides an analysis of T2DM as a systemic disease, and analyses modern approaches to treatment pathology, issues of modern pharmacotherapy and its effectiveness, the possibility of combining pharmacotherapy and herbal medicine to improve the effectiveness of the treatment of T2DM and its complications. The review looks at the prospects for greater use of herbal medicine in diabetes to reduce the risk of severe complications, improve the quality and life expectancy of individuals, sufferers of this disease.

Keywords: Type 2 diabetes, T2DM, diabetogenesis, pharmacotherapy, herbal medicine.

Download file:

References
  1. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Kulina GR, Rayfield EJ. The role of glucagon in the pathophysiology and management of diabetes. Endocrine Practice. 2016;22(5):612-21.
  2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
  3. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology. 2009;150(3):1155-64.
  4. Swetha NK. Comparison of fasting blood glucose and post prandial blood glucose with HbA1c in assessing the glycemic control. International J of Healthcare and Biomedical Research. 2014;2(3):134-9.
  5. Lee YH, Wang M-Y, Yu X-X, Unger RH. Glucagon is the key factor in the development of diabetes. Diabetologia. 2016;59(7):1372-5.
  6. Lund A, Bagger J, Christensen M, Knop F, Vilsboll T. Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep. 2014;14:1-7.
  7. Kelly RP, Garhyan P, Raddad E, Fu H, Lim CN, Prince MJ, et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015;17(4):414-22.
  8. Hasenour CM, Berglund ED, Wasserman DH. Emerging role of amp activated protein kinase in endocrine control of metabolism in the liver. Mol Cell Endocrinol. 2013;66(2):152-162. Available from: https://doi.org/10.1016/j. mce.2012.06.018.
  9. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513-48. Available from: https://doi.org/10.1152/physrev.00013.
  10. Davidson JA, Holland WL, Roth MG, Wang M-Y, Lee Y, Yu X, et al. Glucagon therapeutics: dawn of a new era for diabetes care. Diabetes/Metabolism. Research and Reviews. 2016;32(7):660-5.
  11. Lund A, Bagger JI, Christensen M, Knop FK, Vilsboll T. Glucagon and type 2 diabetes: the return of the alpha cell. Current Diabetes Reports. 2014;14:555.
  12. Holst J, Vilsboll T, Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.
  13. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016:18(3):203-16.
  14. Ben-Shlomo Sh, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. Journal of Hepatology. 2011;54(6):1214-23.
  15. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a highfat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31:1285-97.
  16. Edgerton DS, Ramnanan ChJ, Grueter CA, Johnson KMS, Doss ML, Neal W, et al. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes. 2009;58:2766-75.
  17. Watanabe T, Tamura Y, Kakehi S, Funayama T, Gastaldelli A, Takeno K, et al. Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study. J Diabetes Investig. 2015;6:164-72.
  18. Heni M, Kullmann S, Gallwitz B, Häring HU, Preissl H, Fritsche A. Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans. Mol Metab. 2015;4:971-6.
  19. Vijay-Kumar M, Aitken J, Carvalho F, Cullender T, Mwangi S, Srinivasan S et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228-31.
  20. Goodrich J, Waters J, Poole A, Sutter J, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell. 2014;159:789-99.
  21. Zhang L, Bahl M, Roager H, Fonvig C, Hellgren L, Frandsen H, et al. Environmental spread of microbes impacts the development of metabolic phenotypes in mice transplanted with microbial communities from humans. ISME J. 2017;11:676-90.
  22. Bordenstein S, Theis K. Host biology in light of the microbiome: ten principles of holobionts and hologenomes. PLoS Biol. 2015;13(8):e1002226. Available from: https://doi.org/10.1371/journal.pbio.1002226.
  23. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41-50.
  24. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Molecular Aspects of Medicine. 2013;34(1):39-58.
  25. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Molecular Aspects of Medicine. 2013;34(1):39-58.
  26. Ussar S, Fujisaka S, Kahn C. Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. Mol Metab. 2016;5:795-803.
  27. Komaroff AL. The microbiome and risk for obesity and diabetes. JAMA. 2017;317(4):355-6.
  28. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, et al. Dietary polyphenols promote growth of the gut bacterium Akkermansia muciniphila and attenuate high-fat diet-induced metabolic syndrome. Diabetes. 2015;64(8):2847-58.
  29. Blandino G, Inturri R, Lazzara F, Rosa MD, Malaguarnera L. Impact of gut microbiota on diabetes mellitus. Diabetes & metabolism. 2016;763:13. Available from: https://doi.org/10.1016/j.diabet.2016.04.004.
  30. Heni M, Kullmann S, Preissl H, Fritsche A, Häring H-U. Impaired insulin action in the human brain: causes and metabolic consequences. Nature Reviews Endocrinology. 2015;11:701-11.
  31. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014;63(7):2232-43.
  32. Shpakov AO, Derkach KV, Berstein LM. Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Science. 2015;1(3):FSO25. Available from: https://doi. org/10.4155/fso.15.23.
  33. Liu CC, Hu J, Tsai CW, Yue M, Melrose HL, Kanekiyo T, Bu G. Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. The Journal of Neuroscience. 2015;35(14):5851-9.
  34. Ferris HA, Kahn CR. Unraveling the paradox of selective insulin resistance in the liver: the brain–liver connection. Diabetes. 2016;65(6):1481-3.
  35. Scherer T, Lindtner C, O’Hare J, Hackl M, Zielinski E, Freudenthaler A, et al. Insulin regulates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes. 2016;65(6):1511-20.
  36. Myers MG, Olson DP, Low MJ, Elias CF. Brain regulation of feeding and energy homeostasis. Metabolic syndrome: A comprehensive textbook. 2016:347-68.
  37. Cătoi AF, Pârvu A, Mureşan A, Busetto L. Metabolic mechanisms in obesity and type 2 diabetes: Insights from bariatric/metabolic surgery. Obesity Facts. 2015;8(6):350-63.
  38. Gonçalves CG, Glade MJ, Meguid MM. Metabolically healthy obese individuals: Key protective factors. Nutrition. 2016;32(1):14-20.
  39. Kullmann S, Heni M, Fritsche A, Preissl H. Insulin action in the human brain: evidence from neuroimaging studies. Journal of Neuroendocrinology. 2015;27(6):419-23.
  40. Polyzos SA, Mantzoros CS. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism: clinical and experimental. 2015;64(1):5.
  41. Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. Nature Reviews Neuroscience. 2015;16(11):660-71.
  42. Pearson-Leary J, Jahagirdar V, Sage J, McNay EC. Insulin modulates hippocampally-mediated spatial working memory via glucose transporter-4. Behavioural Brain Research. 2018;338:32-9.
  43. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet. 2017;389(10085):2239-51.
  44. Inzucchi SE, Bergenstal RM, Buse JB, Diaman M, Ferrannin E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9. Available from: https://doi.org/10.2337/dc14-2441.
  45. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Journal of the Academy of Nutrition and Dietetics. 2015;115(9):1447-63.
  46. Fan R, Xu M, Wang J, Zhang Z, Chen Q, Li Y, et al. Sustaining effect of intensive nutritional intervention combined with health education on dietary behavior and plasma glucose in type 2 diabetes mellitus patients. Nutrients. 2016;8(9):560.
  47. Franz MJ. Diabetes nutrition therapy: effectiveness, macronutrients, eating patterns and weight management. The American Journal of the Medical Sciences. 2016;351(4):374-9.
  48. Smirnova ОМ, Kononenko IV. Gipoglikemiziruyushchaya terapiya bol’nykh sakharnym diabetom 2 tipa i ishemicheskoy bolezn’yu serdtsa, v tom chisle s infarktom miokarda i posle interventsionnykh vmeshatel’stv [Hypoglycemic therapy of patients with type 2 diabetes mellitus and coronary heart disease, including with myocardial infarction and after interventions]. Sakharnyy diabet. 2012;3:27-38.
  49. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015; 38(3): 376-83. Available from: https://doi.org/10.2337/dc14- 1142
  50. Rosenstock J, Chuck L, González-Ortiz M, Merton K , Craig J, Capuano G, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care. 2016;39(3):353-62.
  51. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2016;164:740-51.
  52. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab. 2009;35(5):385-91.
  53. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313-24
  54. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Сonsensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocrine Practice. 2016;22(1):84-113.
  55. Dedov II, Shestakova MV, Ametov AS, Antsiferov MB, Galstyan GR, Mayorov AYu, i dr. Initsiatsiya i intensifikatsiya sakharosnizhayushchey terapii u bol’nykh sakharnym diabetom 2 tipa: obnovlenie konsensusa soveta ekspertov Rossiyskoy assotsiatsii endokrinologov [Initiation and intensification of sugar-lowering therapy in patients with type 2 diabetes mellitus: updating the consensus of the expert council of the Russian association of endocrinologists]. Sakharnyy diabet. 2015;1:5-23.
  56. Kaydashev IP. Nf-Kb-signalizatsiya kak osnova razvitiya sistemnogo vospaleniya, insulinoreziztentnosti, lipotoksichnosti, sakharnogo diabeta 2 tipa i ateroskleroza [Nf-Kb signaling as the basis for the development of systemic inflammation, insulin resistance, lipotoxicity, type 2 diabetes mellitus and atherosclerosis]. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2011;3:35-45.
  57. Sokolova LК. Sakharnyy diabet 2-gо tipa. Rol’ semeynogo vracha [Type 2 diabetes mellitus. The role of the family doctor]. Vrachu-praktiku. 2012;1:70-4.
  58. Pankiv VІ. Ingibitor alfa-glyukozidazi vogliboz: novi mozhlivosti likuvannya і profilaktikitsu krovogo diabetu [Alpha-glucosidase inhibitor voglibosis: new options for treatment and prevention of blood diabetes]. Mezhdunarodnyy endokrinologicheskiy zhurnal. 2013;7:35-8.
  59. Kadzharyan VG, Kapshitar NI. Novoe v lechenii sakharnogo diabeta 2 tipa [New in type 2 diabetes treatment]. Zaporozhskiy meditsinskiy zhurnal. 2014;1:74-9.
  60. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;86:566-92. Available from: https://doi.org/10.1038/nrendo.
  61. Liebl A, Khunti K, Orozco-Beltran D, Yale J-F. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clinical medicine insights. Endocrinology and Diabetes. 2015;8:13.
  62. Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clinical Endocrinology. 2012;77(2):215-23.
  63. Ishikawa M, Takai M, Maeda H, Kanamori A, Kubota A, Amemiya H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and insulin in type 2 diabetic patients: The ASSIST-K Study. J Clin Med Res. 2015;7(8):607-12.
  64. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015;373:2117-28
  65. Jahagirdar V, Barnett AH. Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15:2429-41.
  66. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369- 84.
  67. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017; 127:4217-27.
  68. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524-36.
  69. MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;8:241-53.
  70. Henry RR, Klein EJ, Han J, Iqbal N. Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 Study. Diabetes Technol Ther. 2016;18(11):677-86.
  71. Ametov AS, Gusenbekova DG. Rol’ ingibitorov DPP-4 v korrektsii narusheniy zhirovogo obmena u patsientov s SD 2 tipa i ozhireniem [The role of DPP-4 inhibitors in the correction of fat metabolism disorders in patients with type 2 diabetes and obesity]. Sakharnyy diabet. 2015;18(3):85-92.
  72. Solomina ЕА. Insulinoterapiya SD 2 tipa: effektivnost’, profil’ bezopasnosti i perenosimost’ rinsulina Р i rinsulina NPKh [Type 2 diabetes insulin therapy: efficacy, safety profile, and tolerability of rinsulin P and rinsulin NPH]. Endokrinologiya: novosti, mneniya, obuchenie. 2016;1:81-7.
  73. Makino H, Tanaka A, Hosoda H, Koezuka R, Tochiya M, Ohata Y, et al. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes. Diabetic Medicine. 2016;33(12):1737-43.
  74. Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, i dr. Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nym sakharnym diabetom [Algorithms for specialized medical care for patients with diabetes]. Sakharnyy diabet. 2017;20(IS):1-112.
  75. Smirnov АV, Snigur GL, Yakovlev АТ, Mednikov DS, Kurkin DV, Volotova ЕV, i dr. Kolichestvennaya kharakteristika patomorfologicheskikh izmeneniy v endokrinnoy chasti podzheludochnoy zhelezy krys pri modelirovanii eksperimental’nogo streptozototsin-indutsirovannogo sakharnogo diabeta [Quantitative characterization of pathomorphological changes in the endocrine part of the pancreas of rats when modeling experimental streptozotocin-induced diabetes mellitus]. Volgogradskiy nachno-meditsinskiy zhurnal. 2015;4:21-4.
  76. Tretyakov АYu, Romasenko LV, Ermilov ОV, Shilenok VN, Zakharchenko SP. Rasprostrannyonnost’ narusheniy uglevodnogo obmena, osobennosti insulinemii i insulinoresistentnosti pri sakharnom diabete 2 tipa u bol’nykh shizofreniey [The prevalence of carbohydrate metabolism disorders, features of insulinemia and insulin resistance when type 2 diabetes mellitus in patients with schizophrenia]. Vestnik novykh meditsinskikh tekhnologiy. 2018;25(2):43-7.
  77. Mankovskiy BN, Zherdeva NN. Insulinoterapiya. Chto novogo? [Insulin therapy. What’s new?] Mezhdunarodnyy zhurnal endokrinologii. 2013;3:43-6.
  78. Zalevskaya АG, Verbovaya NI, Rodionova ТI, Vikulova ОК, Shestakova MV. Bazal’naya insulinoterapiya u patsientov s sakharnym diabetom 2 tipa s neudovletvoritel’nym kontrolem glikemii na peroral’noy sakharosnizhayushchey terapii: rezul’taty pryamogo sravnitel’nogo issledovaniya analogov insulina Lantus i Levemir [Basal insulin therapy in patients with type 2 diabetes mellitus with poor glycemic control on oral hypoglycemic therapy: results of a direct comparative study of insulin analogues Lantus and Levemir]. Sakharnyy diabet. 2010;2:106-12.
  79. Dedov II, Shestakova MV, Abusuev SА. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii) [Optimization and intensification of insulin therapy for type 2 diabetes mellitus (clinical recommendations)]. Sakharnyy diabet. 2010;5:9-16.
  80. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485-502.
  81. Dedov II, Shestakova MV. Insulin degludek – novyy analog insulina sverkhdlitel’nogo deystviya [Degludec insulin – a new analogue of insulin of extra long action]. Sakharnyy diabet. 2014;2:91-104.
  82. Georgescu A, Alexandru N, Nemecz M, Titorencu I, Popov D. Irbesartan administration therapeutically influences circulating endothelial progenitor cell and microparticle mobilization by involvement of pro-inflammatory cytokines. Eur J Pharmacol. 2013;711:27-35.
  83. Ametov АS. Sakharnyy diabet 2 tipa: problemy i resheniya [Type 2 diabetes: problems and solutions]. Moscow, RF: GEOTAR-Media; 2012. 704 p.
  84. Liebl A, Khunti K, Orozco-Beltran D, Yale J-F. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clinical medicine insights. Endocrinology and Diabetes. 2015;8:13-9.
  85. Dedov II, Shestakova MV, Ametov АS, Anciferov МB, Galstyan GR, Mayyorov АYu, i dr. Konsensus soveta ekspertov Rossiyskoy Assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhayushchey terapii u bol’nykh sakharnym diabetom 2 tipa [Consensus of the expert council of the Russian Association of Endocrinologists on the initiation and intensification of antidiabetic therapy in patients with type 2 diabetes]. Sakharnyy diabet. 2011;4:6-17.
  86. Dedov II. Sakharnyy diabet – opasneyshiy vyzov mirovomu soobshchestvu [Diabetes mellitus – the most dangerous challenge to the world community]. Vestnik RAMN. 2012;1:7-13.
  87. Dedov II. Innovatsionnye tekhnologii v lechenii i profilaktike sakharnogo diabeta i ego oslozhneniy [Innovative technologies in the treatment and prevention of diabetes and its complications]. Sakharnyy diabet. 2013;3:2-10.
  88. Fyodorova ОL. Fitoimmunokorrektsiya v formate sovremennykh meditsinskikh tekhnologiy i standartov [Phytoimmunocorrection in the format of modern medical technologies and standards]. Ukrainskiy meditsinskiy zhurnal. 2014;2:19-25.
  89. Barnaulov ОD. Sravnitel’naya otsenka vliyaniya fitopreparatov iz rasteniy flory Rossii na kontsentratsiyu insulina i glyukozy v krovi krys s eksperimental’nym alloksanovym diabetom [Comparative evaluation of the effect of herbal preparations from plants of the flora of Russia on the concentration of insulin and glucose in the blood of rats with experimental alloxan diabetes]. Psikhofarmakologiya i biologicheskaya narkologiya. 2008;8:2484-90.
  90. Barnaulov ОD. Sravnitel’naya otsenka protivodiabeticheskoy aktivnosti lekarstvennykh rasteniy poryadka Vereskovye [Comparative evaluation of the antidiabetic activity of medicinal plants of the Heather order]. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii. 2011;9(2):68-74.
  91. Kozlova АP, Koroshenko GА, Ayzman RI. Kakie komponenty rasteniya Curcuma Longa okazivayut gipoglikemicheskiy effekt pri sakharnom diabete? [What components of the Curcuma Longa plant have a hypoglycemic effect in diabetes?]. Vestnik Novosibirskogo gosudarstvennogo pedagoicheskogo universiteta. 2016;3:167-73.
  92. Chekina NА, Chukaev SА, Nikolaev SМ. Sakharnyy diabet: vozmozhnosti farmakoterapii s ispol’zovaniem sredstv rastitel’nogo proiskhozhdeniya [Diabetes mellitus: possibilities of pharmacotherapy with the use of herbal remedies]. Vestnik Buryatskogo gosuniversiteta. 2010;12:71-8.
  93. Aizman RI, Koroshchenko GA, Gaidarova AP, Lukanina SN, Subotyalov MA. The mechanisms of plant rhizome curcuma longa action on carbohydrate metabolism in alloxan-induced diabetes mellitus rats. American Journal of Biomedical Research. 2015;3(1):1-5.
  94. Dzhafarova RE. Izuchenie deystviya fitokompleksa «Antidiabet» i sbora «Mirfazin» na soderzhanie sakhara v plazme krovi i glikogena v pecheni i myshechnoy tkani [Study of the effect of the phytocomplex “Antidiabetes” and the collection “Mirfazin” on the sugar content in blood plasma and glycogen in the liver and muscle tissue]. Vestnik Rossiyskoy Voenno-meditsinskoy akademii. 2013;4:172-4.
  95. Koroshenko GА, Gaydarova АP, Ayzman RI, Subotyalov МА. Vozmozhnost’ primeneniya fitopreparatov dlya podderzhaniya gomeostazа organizma pri patologii [The possibility of using phytopreparations to maintain the body’s homeostasis in pathology]. Ukrainskiy biofarmatsevtichniy zhurnal. 2014;4:45-9.
  96. Abushakhmanova АKh, Piven LI, Kim ТV. Fitoterapiya gestatsinnogo sakharnogo diabeta [Phytotherapy of gestational diabetes]. Vestnik KazNMU. 2014;4:438-40.
  97. Azhunova TA, Lemza SV, Linkhoeva EL. Farmakoterapevticheskaya effektivnost’ kompleksnogo rastitel’nogo sredstva pri eksperimental’nom diabete [Pharmacotherapeutic efficacy of a complex herbal remedy for experimental diabetes]. Byulliten VSNTS SO RANM. 2011;1:104-8.
  98. Lacroix IM, Li-Chan EC. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes. Molecular Nutrition & Food Research. 2014;58(1):61-78.
  99. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.
  100. Visavadiya N. Diabetes: updates on abnormal metabolic signaling pathways and possible medicinal plant-based targets. Ann Food Sci Nutraceuticals. 2016;1(1):9-20.
  101. Kiselyova TL, Smirnova YuА. Lekarstvennye rasteniya v mirovoy meditsinskoy praktike: gosudarstvennoe regulirovanie nomenklatury i kachestva [Medicinal plants in world medical practice: state regulation of nomenclature and quality]. Moscow, RF: Isd-vо Professional’noy assotsiatsii naturoterapevtov; 2009. 295 p.
  102. Kiselyova TL, Tutelyan VА, Kochetkova АА, Kiselyova МА. Integrativnye podkhody k nauchno obosnovannoy fitoterapii sakharnogo diabeta i sozdaniyu spetsializirovannykh pishchevykh produktov dlya bol’nykh sakharnym diabetom 2 tipa [Integrative approaches to evidence-based fitotherapy for diabetes mellitus and the creation of specialized foods for patients with type 2 diabetes]. Chelovek i ego zdorov’e. 2015;3:110-20.
  103. Tutelyan VА, Kiselyova TL, Kochetkova АА, Kiselyova МА. Metodologicheskie podkhody k sozdaniyu retseptur spetsializirovannykh pishchevykh produktov dlya bol’nykh sakharnym diabetom na osnove opyta otechestvennoy traditsionnoy meditsiny [Methodological approaches to the creation of specialized food formulations for patients with diabetes mellitus based on the experience of domestic traditional medicine]. Traditsionnaya meditsina. 2015;3:25-33.
  104. Kalmykov S, Kalmykova Yu. Kharakteristika lekarstvennykh rasteniy, primenyaemykh v fitoterapii sakharnogo diabeta 2-go tipa [Characteristics of the medicinal plants used in herbal medicine type 2 diabetes]. Slobozhanskiy naukovo-sportivniy visnik. 2016;3:53-8
  105. Kunakova RV, Zaynullin RA, Khusnutdinova EК, Yalaev BI, Segura EP, Ilyina AD. Rasteniya kak perspektivnye istochniki ingibitorov amilazy pri razrabotke funktsional’nykh produktov pitaniya i profilaktiki sakharnogo diabeta [Plants as promising sources of amylase inhibitors in the development of functional foods and the prevention of diabetes]. Obshchaya biologiya. 2016;21:6-15.
  106. Nuraliev YuN, Sharofova MU, Sagdieva ShS. O sushchnosti i tyazhyolykh posledstviyakh taktiki terapii sakharnogo diabeta po printsipu «podobnoe podobnym» [Essence and severe consequences of therapy tactics of diabetes mellitis by principle «like cures like»]. Vestnik Avitsenny [Avicenna Bulletin]. 2015;3:151-6
  107. Sharofova M, Aldybiat I, Sagdieva Sh, Burkhonova N, Nuraliev Yu, Rahimi F, Mirshahi M. Molecular approach to determine the hot and cold temperaments in plants according Avicenna concepts, the role of magnesium. Vestnik Avitsenny [Avicenna Bulletin]. 2018;20(4):421-6. Available from: https://doi. org/10.25005/2074-0581-2018-20-4-421-426.
  108. Park Ch, Lee J-S. Banaba: The natural remedy as antidiabetic drug. Biomedical Research. 2011;22(2):125-9.
  109. Abu Ali ibn Sina (Аvicennа). Sochineniya. Т. 12. Kanon vrachebnoy nauki. Kniga pervaya [Canon of medical science. Book one]. Dushanbe, RT: Donish; 2010. 735 p.
  110. Kiselyova TL. Kineticheskiy sinergizm v fitoterapii: traditsionnye preparaty s tochki zreniya sovremennykh nauchnykh predstavleniy [Kinetic synergy in fitotherapy: traditional products from the point of view of modern scientific concepts]. Traditsionnaya meditsina. 2011;2:50-8.
  111. Kiselyova TL, Dronova МА. Sinergicheskie asrekty sovremennoy fitofarmakoterapii [Synergistic aspects of modern phytopharmacotherapy]. Novosti meditsiny i farmatsii. 2012;7:24-7.
  112. Aisa HA, Nuraliev Y, Habasi M, Sharofova M, Bahromova Z. Contribution of Ibn Sina (Avicenna) to the therapy of vitiligo. Dushanbe, RT: Contrast; 2015. 344 p.
  113. Miraj S, Alesaeidi S, Kiani S. A systematic review of the relationship between dystemprament (sue Mizaj) and treatments and management of diseases (Ilaj and Eslah-e-Mizaj). Electronic Physician. 2016;8(12):3378-84.
  114. Dadashina YuV, Zharkova LP. Primenenie indikatorov kompensatsii uglevodnogo obmena u bol’nykh sakharnym diabetom 2 tipa [The use of indicators of compensation for carbohydrate metabolism in patients with type 2 diabetes]. Vrach. 2012;3:81-4.
  115. Karomatov ID, Nabieva ZT, Ganiev RM. Plody granatov v profilaktike i lechenii sakharnogo diabeta i serdechno-sosudistykh zabolevaniy [Fruits of pomegranates in prevention and treatment of diabetes and warm and vascular diseases]. Biologiya i integrativnaya meditsina. 2018;2:91-100.
  116. Karomatov ID, Akhmedova ShM, Aminova NN. Perspektivy primeneniya imbirya pri lechenii sakharnogo diabeta [The prospects of application of ginger at treatment of diabetes]. Biologiya i integrativnaya meditsina. 2018;4:198- 210.
  117. Karomatov ID, Aslanova DK. Vozmozhnosti ispol’zovaniya preparatov kornya imbirya pri sakharnom diabete (obzor literatury) [Possibilities of use of medicines of the root of ginger at diabetes (the review of literature)]. Biologiya i integrativnaya meditsina. 2019;1:78-89.
  118. Karomatov ID, Mavlonov SS. Chernushka pri lechenii i profilaktike sakharnogo diabeta i zabolevaniy zheludochno-kishechnogo trakta (obzor literatury) [Black cumin at treatment and prevention of diabetes and diseases of digestive tract (the review of literature)]. Biologiya i integrativnaya meditsina. 2019;1:173-84.

Authors' information:

Sharofova Mizhgona Umedzhonovna
Candidate of Medical Sciences, Head of the Biotechnology Laboratory, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Director of Institute of Avicenna’s Medicine and Pharmacology
ORCID ID: 0000-0002-7155-7194

Sagdieva Shoista Samarovna
Candidate of Medical Sciences, Senior Researcher, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Scientific Secretary of the Institute of Avicenna’s Medicine and Pharmacology
ORCID ID 0000-0002-0595-3666

Yusufi Salomudin Dzhabbor
Academician of the Academy of Medical Sciences of the Republic of Tajikistan, Doctor of Pharmaceutical Sciences, Full Professor, Vice Rector for Science and Publishing, Avicenna Tajik State Medical University
ORCID ID 0000-0002-1442-9508

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Sharofova Mizhgona Umedzhonovna
Candidate of Medical Sciences, Head of the Biotechnology Laboratory, Department of Innovative Pharmacology and Experimental Medicine of the Center for Research in Innovative Technologies, the Academy of Sciences of the Republic of Tajikistan; Director of Institute of Avicenna’s Medicine and Pharmacology

734003, Republic of Tajikistan, Dushanbe, 229/3 Ayni Street

Tel.: +992 (918) 614123

E-mail: mijgona72@mail.ru

◄ Back to the list